NEW YORK, June 2, 2017 /PRNewswire/ --
On Thursday, the NASDAQ Composite ended the day at 6,246.83, up 0.78%; the Dow Jones Industrial Average edged 0.65% higher, to finish at 21,144.18; and the S&P 500 closed at 2,430.06, marginally gaining 0.76%. Gains were broad based as all nine sectors finished the trading session in green. Stock-Callers.com has initiated research reports on the following Biotechnology stocks: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), Cara Therapeutics Inc. (NASDAQ: CARA), Cerus Corp. (NASDAQ: CERS), and Concert Pharmaceuticals Inc. (NASDAQ: CNCE). Learn more about these stocks by downloading their comprehensive and free reports at:
Hayward, CA, US headquartered Anthera Pharmaceuticals Inc.'s stock finished Thursday's session 4.35% higher at $1.68 with a total trading volume of 141,420 shares. The Company's shares are trading 37.26% below their 50-day moving average. Shares of the Company, which focuses on the development and commercialization of medicines for patients with unmet medical needs, have a Relative Strength Index (RSI) of 31.34. ANTH complete research report is just a click away and free at:
On Thursday, shares in Stamford, Connecticut headquartered Cara Therapeutics Inc. recorded a trading volume of 1.51 million shares. The stock ended the session 4.77% higher at $17.35. The Company's shares have advanced 16.29% in the last one month, 3.52% in the previous three months, and 86.76% on an YTD basis. The stock is trading 2.82% above its 50-day moving average and 45.54% above its 200-day moving average. Moreover, shares of Cara Therapeutics, which focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the US, have an RSI of 55.97. The complimentary report on CARA can be downloaded at:
Concord, California headquartered Cerus Corp.'s shares closed the day 3.06% higher at $2.36. The stock recorded a trading volume of 697,791 shares. The Company's shares are trading 36.69% below their 50-day moving average. Additionally, shares of Cerus, which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety, have an RSI of 29.39. Sign up for your complimentary research report on CERS at:
Shares in Lexington, Massachusetts headquartered Concert Pharmaceuticals Inc. finished 0.88% higher at $12.67. The stock recorded a trading volume of 156,768 shares. The Company's shares have advanced 31.98% in the previous three months and 23.13% on an YTD basis. The stock is trading above its 200-day moving average by 10.19%. Furthermore, shares of Concert Pharma, which operates as a clinical stage biopharmaceutical company, have an RSI of 31.47. Get free access to your research report on CNCE at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA